WTX-A / WaveBreak Therap - LARVOL DELTA

WaveBreak Presents New Preclinical Data at MDS 2023 Demonstrating the Efficacy of its First-in-Class, Small-Molecule Inhibitors of Toxic Oligomers for Blocking Progression of Both α-Synuclein Oligomers and Aggregates in Models of Parkinson’s Disease (PRNewswire) - "WaveBreak announced today the presentation of new preclinical data for its first-in-class, oral inhibitors of α-synuclein oligomer generation demonstrating efficacy for blocking the progression of both α-synuclein oligomers and aggregates in cell and mouse models of Parkinson's disease....WTX-A inhibited 90% of both primary nucleation and secondary nucleation—the molecular mechanisms at the source of α-synuclein oligomer formation—with high specificity for α-synuclein, showing no inhibition in tau and Aβ42 amyloid aggregation assays....In the gold-standard M83 transgenic mouse model (expressing aggregation-prone human A53T mutant, seeded with human fibrils), WTX-A reduced α-synuclein aggregates by ~70%—substantively more than measured with a different first-generation WaveBreak small molecule."

Preclinical • CNS Disorders • Parkinson's Disease